Skip to main content
SpringerLink
Log in

Alveolar Soft Part Sarcoma

  • Chapter
  • First Online:
Rare Sarcomas

  • 346 Accesses

Abstract

Alveolar Soft Part Sarcoma (ASPS) is a rare orphan malignant soft tissue tumor of uncertain cellular lineage with a somewhat indolent clinical course. It has been first described in 1952 by Christopherson, a fellow in surgical pathology at Memorial Sloan Kettering Cancer Center who reported 12 cases with similar clinical and pathology features (Christopherson et al., Cancer 5:100–111, 1952). Indeed, ASPS present a very distinctive clinical pattern compared to other sarcomas with a peculiar natural history marked by a high prevalence of brain metastasis, predominance in female patients, chemoresistance, and sensitivity to tyrosine kinase inhibitors. ASPS is driven by a specific translocation that involves chromosome X. Accurate diagnosis requires trained pathologists and molecular testing to lead the treatment accordingly, which should be based surgery if resectable and on tyrosine kinase inhibitors upfront in metastatic setting. This rare disease strikes the need to collaborate between expert centers worldwide and cross the boundaries between pediatric and adult oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol. 2006;59:1127–32.

    Google Scholar 

  2. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer. 1989;63:1–13.

    Google Scholar 

  3. Liebl LS, Elson F, Quaas A, Gawad KA, Izbicki JR. Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res. 2007;27:2897–902.

    Google Scholar 

  4. Das KK, Singh RK, Jaiswal S, Agrawal V, Jaiswal AK, Behari S. Alveolar soft part sarcoma of the frontal calvarium and adjacent frontal lobe. J Pediatr Neurosci. 2012;7:36–9.

    Google Scholar 

  5. Ju HU, Seo KW, Jegal Y, Ahn J-J, Lee YJ, Kim YM, Oak C, Ra SW. A case of alveolar soft part sarcoma of the pleura. J Korean Med Sci. 2013;28:331–5.

    Google Scholar 

  6. Shaddix KK, Fakhre GP, Nields WW, Steers JL, Hewitt WR, Menke DM. Primary alveolar soft-part sarcoma of the liver: anomalous presentation of a rare disease. Am Surg. 2008;74:43–6.

    Google Scholar 

  7. Kim YD, Lee CH, Lee MK, Jeong YJ, Kim JY, Park DY, Sol MY. Primary alveolar soft part sarcoma of the lung. J Korean Med Sci. 2007;22:369–72.

    Google Scholar 

  8. Yaziji H, Ranaldi R, Verdolini R, Morroni M, Haggitt R, Bearzi I. Primary alveolar soft part sarcoma of the stomach: a case report and review. Pathol Res Pract. 2000;196:519–25.

    Google Scholar 

  9. Wu J, Brinker DA, Haas M, Montgomery EA, Argani P. Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol. 2005;13:81–5.

    Google Scholar 

  10. Zhang L, Tang Q, Wang Z, Zhang X. Alveolar soft part sarcoma of the uterine corpus with pelvic lymph node metastasis: case report and literature review. Int J Clin Exp Pathol. 2012;5:715–9.

    Google Scholar 

  11. Roma AA, Yang B, Senior ME, Goldblum JR. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol. 2005;24:131–5.

    Google Scholar 

  12. Amin MB, Patel RM, Oliveira P, Cabrera R, Carneiro V, Preto M, Balzer B, Folpe AL. Alveolar soft-part sarcoma of the urinary bladder with urethral recurrence: a unique case with emphasis on differential diagnoses and diagnostic utility of an immunohistochemical panel including TFE3. Am J Surg Pathol. 2006;30:1322–5.

    Google Scholar 

  13. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48–57.

    Google Scholar 

  14. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone. Lyon: IARC; 2013.

    Google Scholar 

  15. Christopherson WM, Foote FW, Stewart FW. Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis. Cancer. 1952;5:100–11.

    Google Scholar 

  16. Masson P. Tumeurs humaines histologie, diagnostics et techniques. Paris: Librairie Maloine; 1956.

    Google Scholar 

  17. Persson S, Willems JS, Kindblom LG, Angervall L. Alveolar soft part sarcoma. An immunohistochemical, cytologic and electron-microscopic study and a quantitative DNA analysis. Virchows Arch A Pathol Anat Histopathol. 1988;412:499–513.

    Google Scholar 

  18. Mukai M, Torikata C, Iri H, Mikata A, Hanaoka H, Kato K, Kageyama K. Histogenesis of alveolar soft part sarcoma. An immunohistochemical and biochemical study. Am J Surg Pathol. 1986;10:212–8.

    Google Scholar 

  19. Mukai M, Torikata C, Shimoda T, Iri H. Alveolar soft part sarcoma. Assessment of immunohistochemical demonstration of desmin using paraffin sections and frozen sections. Virchows Arch A Pathol Anat Histopathol. 1989;414:503–9.

    Google Scholar 

  20. Denk H, Krepler R, Artlieb U, Gabbiani G, Rungger-Brändle E, Leoncini P, Franke WW. Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol. 1983;110:193–208.

    Google Scholar 

  21. Foschini MP, Ceccarelli C, Eusebi V, Skalli O, Gabbiani G. Alveolar soft part sarcoma: immunological evidence of rhabdomyoblastic differentiation. Histopathology. 1988;13:101–8.

    Google Scholar 

  22. Matsuno Y, Mukai K, Itabashi M, Yamauchi Y, Hirota T, Nakajima T, Shimosato Y. Alveolar soft part sarcoma. A clinicopathologic and immunohistochemical study of 12 cases. Acta Pathol Jpn. 1990;40:199–205.

    Google Scholar 

  23. Rosai J, Dias P, Parham DM, Shapiro DN, Houghton P. MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. Am J Surg Pathol. 1991;15:974–81.

    Google Scholar 

  24. Miettinen M, Ekfors T. Alveolar soft part sarcoma. Immunohistochemical evidence for muscle cell differentiation. Am J Clin Pathol. 1990;93:32–8.

    Google Scholar 

  25. Sciot R, Dal Cin P, De Vos R, Van Damme B, De Wever I, Van den Berghe H, Desmet VJ. Alveolar soft-part sarcoma: evidence for its myogenic origin and for the involvement of 17q25. Histopathology. 1993;23:439–44.

    Google Scholar 

  26. Enzinger and Weiss’s soft tissue tumors, 6th ed. https://www.elsevier.com/books/enzinger-and-weisss-soft-tissue-tumors/goldblum/978-0-323-08834-3. Accessed 2 Dec 2017.

  27. Wang NP, Bacchi CE, Jiang JJ, McNutt MA, Gown AM. Does alveolar soft-part sarcoma exhibit skeletal muscle differentiation? An immunocytochemical and biochemical study of myogenic regulatory protein expression. Mod Pathol. 1996;9:496–506.

    Google Scholar 

  28. Gómez JA, Amin MB, Ro JY, Linden MD, Lee MW, Zarbo RJ. Immunohistochemical profile of myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma. Arch Pathol Lab Med. 1999;123:503–7.

    Google Scholar 

  29. Mukai M, Torikata C, Iri H, Mikata A, Sakamoto T, Hanaoka H, Shinohara C, Baba N, Kanaya K, Kageyama K. Alveolar soft part sarcoma. An elaboration of a three-dimensional configuration of the crystalloids by digital image processing. Am J Pathol. 1984;116:398–406.

    Google Scholar 

  30. Fisher ER, Reidbord H. Electron microscopic evidence suggesting the myogenous derivation of the so-called alveolar soft part sarcoma. Cancer. 1971;27:150–9.

    Google Scholar 

  31. Mukai M, Iri H, Nakajima T, Hirose S, Torikata C, Kageyama K, Ueno N, Murakami K. Alveolar soft-part sarcoma. A review on its histogenesis and further studies based on electron microscopy, immunohistochemistry, and biochemistry. Am J Surg Pathol. 1983;7:679–89.

    Google Scholar 

  32. Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer. 2009;9:22.

    Google Scholar 

  33. Nakano H, Tateishi A, Imamura T, et al. RT-PCR suggests human skeletal muscle origin of alveolar soft-part sarcoma. Oncology. 2000;58:319–23.

    Google Scholar 

  34. Hoshino M, Ogose A, Kawashima H, et al. Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma. Cancer Genet Cytogenet. 2009;190:75–80.

    Google Scholar 

  35. Selvarajah S, Pyne S, Chen E, Sompallae R, Ligon AH, Nielsen GP, Dranoff G, Stack E, Loda M, Flavin R. High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res. 2014;20:1521–30.

    Google Scholar 

  36. Zhang X, Huang CT, Chen J, et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell. 2010;7:90–100.

    Google Scholar 

  37. Mathew T. Evidence supporting neural crest origin of an alveolar soft part sarcoma: an ultrastructural study. Cancer. 1982;50:507–14.

    Google Scholar 

  38. DeSchryver-Kecskemeti K, Kraus FT, Engleman W, Lacy PE. Alveolar soft-part sarcoma—a malignant angioreninoma: histochemical, immunocytochemical, and electron-microscopic study of four cases. Am J Surg Pathol. 1982;6:5–18.

    Google Scholar 

  39. Ackerman LV, Phelps CR. Malignant granular cell myoblastoma of the gluteal region. Surgery. 1946;20:511–9.

    Google Scholar 

  40. Khanolkar VR. Granular cell myoblastoma. Am J Pathol. 1947;23:721–39.

    Google Scholar 

  41. Ravich A, Stout AP, Ravich RA. Malignant granular cell myoblastoma involving the urinary bladder. Ann Surg. 1945;121:361–72.

    Google Scholar 

  42. Smetana HF, Scott WF. Malignant tumors of nonchromaffin paraganglia. Mil Surg. 1951;109:330–49.

    Google Scholar 

  43. Shipkey FH, Lieberman PH, Foote FW, Stewart FW. Ultrastructure of alveolar soft part sarcoma. Cancer. 1964;17:821–30.

    Google Scholar 

  44. Pappo AS, Parham DM, Cain A, Luo X, Bowman LC, Furman WL, Rao BN, Pratt CB. Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. Med Pediatr Oncol. 1996;26:81–4.

    Google Scholar 

  45. Jong R, Kandel R, Fornasier V, Bell R, Bedard Y. Alveolar soft part sarcoma: review of nine cases including two cases with unusual histology. Histopathology. 1998;32:63–8.

    Google Scholar 

  46. Ordóñez NG, Mackay B. Alveolar soft-part sarcoma: a review of the pathology and histogenesis. Ultrastruct Pathol. 1998;22:275–92.

    Google Scholar 

  47. Ordóñez NG, Ro JY, Mackay B. Alveolar soft part sarcoma. An ultrastructural and immunocytochemical investigation of its histogenesis. Cancer. 1989;63:1721–36.

    Google Scholar 

  48. Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, De Bernardi B, Indolfi P, Fossati Bellani F, Carli M. Alveolar soft part sarcoma in children and adolescents: a report from the Soft-Tissue Sarcoma Italian Cooperative Group. Ann Oncol. 2000;11:1445–9.

    Google Scholar 

  49. Evans HL. Alveolar soft-part sarcoma. A study of 13 typical examples and one with a histologically atypical component. Cancer. 1985;55:912–7.

    Google Scholar 

  50. Modern Soft Tissue Pathology MIETTINEN Markku. In: Libr. Lavoisier. https://www.lavoisier.fr/livre/medecine/modern-soft-tissue-pathology-2nd-ed/descriptif_3454990. Accessed 2 Dec 2017.

  51. Ladanyi M, Antonescu CR, Drobnjak M, Baren A, Lui MY, Golde DW, Cordon-Cardo C. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol. 2002;160:1215–21.

    Google Scholar 

  52. Schoolmeester JK, Dao LN, Sukov WR, Wang L, Park KJ, Murali R, Hameed MR, Soslow RA. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. 2015;39:394–404.

    Google Scholar 

  53. Chen X, Yang Y, Gan W, Xu L, Ye Q, Guo H. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma. Medicine (Baltimore). 2015;94(19):e873. https://doi.org/10.1097/MD.0000000000000873.

    Google Scholar 

  54. Tsuji K, Ishikawa Y, Imamura T. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. Hum Pathol. 2012;43:356–63.

    Google Scholar 

  55. Riethdorf S, Reimers N, Assmann V, Kornfeld J-W, Terracciano L, Sauter G, Pantel K. High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006;119:1800–10.

    Google Scholar 

  56. Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313–9.

    Google Scholar 

  57. Jaber OI, Kirby PA. Alveolar soft part sarcoma. Arch Pathol Lab Med. 2015;139:1459–62.

    Google Scholar 

  58. Cykowski MD, Hicks J, Sandberg DI, Olar A, Bridge JA, Greipp PT, Navarro P, Kolodziej S, Bhattacharjee MB. Brain metastasis of crystal-deficient, CD68-positive alveolar soft part sarcoma: ultrastructural features and differential diagnosis. Ultrastruct Pathol. 2015;39:69–77.

    Google Scholar 

  59. Goldberg JM, Fisher DE, Demetri GD, et al. Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res. 2015;21:3178–86.

    Google Scholar 

  60. Cullinane C, Thorner PS, Greenberg ML, Kwan Y, Kumar M, Squire J. Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft-part sarcoma. Implications for cell of origin. Cancer. 1992;70:2444–50.

    Google Scholar 

  61. Joyama S, Ueda T, Shimizu K, Kudawara I, Mano M, Funai H, Takemura K, Yoshikawa H. Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: a case report and review of the literature. Cancer. 1999;86:1246–50.

    Google Scholar 

  62. Uppal S, Aviv H, Patterson F, Cohen S, Benevenia J, Aisner S, Hameed M. Alveolar soft part sarcoma—reciprocal translocation between chromosome 17q25 and Xp11. Report of a case with metastases at presentation and review of the literature. Acta Orthop Belg. 2003;69:182–7.

    Google Scholar 

  63. Aulmann S, Longerich T, Schirmacher P, Mechtersheimer G, Penzel R. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. Histopathology. 2007;50:881–6.

    Google Scholar 

  64. Jin L, Majerus J, Oliveira A, Inwards CY, Nascimento AG, Burgart LJ, Lloyd RV. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR. Diagn Mol Pathol. 2003;12:224–30.

    Google Scholar 

  65. Ishiguro N, Yoshida H. ASPL-TFE3 oncoprotein regulates cell cycle progression and induces cellular senescence by up-regulating p21. Neoplasia. 2016;18:626–35.

    Google Scholar 

  66. Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez P-Y, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68.

    Google Scholar 

  67. Lasry A, Ben-Neriah Y. Senescence-associated inflammatory responses: aging and cancer perspectives. Trends Immunol. 2015;36:217–28.

    Google Scholar 

  68. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol. 2010;22:816–27.

    Google Scholar 

  69. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Laé M, Fisher DE, Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919–29.

    Google Scholar 

  70. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012;118:5894–902.

    Google Scholar 

  71. Kobos R, Nagai M, Tsuda M, et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. J Pathol. 2013;229:743–54.

    Google Scholar 

  72. Lazar AJF, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res. 2007;13:7314–21.

    Google Scholar 

  73. Covell DG, Wallqvist A, Kenney S, Vistica DT. Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets. PLoS One. 2012;7:e48023.

    Google Scholar 

  74. Azizi AA, Haberler C, Czech T, Gupper A, Prayer D, Breitschopf H, Acker T, Slavc I. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 2006;7:521–3.

    Google Scholar 

  75. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008;68:3124–32.

    Google Scholar 

  76. Beckmann H, Su LK, Kadesch T. TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev. 1990;4:167–79.

    Google Scholar 

  77. Hemesath TJ, Steingrímsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA, Fisher DE. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994;8:2770–80.

    Google Scholar 

  78. Kiuru-Kuhlefelt S, El-Rifai W, Sarlomo-Rikala M, Knuutila S, Miettinen M. DNA copy number changes in alveolar soft part sarcoma: a comparative genomic hybridization study. Mod Pathol. 1998;11:227–31.

    Google Scholar 

  79. Craver RD, Heinrich SD, Correa H, Kao YS. Trisomy 8 in alveolar soft part sarcoma. Cancer Genet Cytogenet. 1995;81:94–6.

    Google Scholar 

  80. Chamberlain BK, McClain CM, Gonzalez RS, Coffin CM, Cates JMM. Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study. Hum Pathol. 2014;45:1039–44.

    Google Scholar 

  81. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J, Cooper CS. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15:2233–9.

    Google Scholar 

  82. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159:179–92.

    Google Scholar 

  83. Argani P, Ladanyi M. Recent advances in pediatric renal neoplasia. Adv Anat Pathol. 2003;10:243–60.

    Google Scholar 

  84. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg. 2006;41:187–93.

    Google Scholar 

  85. Ferrari A, Casanova M, Collini P, et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:4021–30.

    Google Scholar 

  86. Wang H, Jacobson A, Harmon DC, Choy E, Hornicek FJ, Raskin KA, Chebib IA, DeLaney TF, Chen Y-LE. Prognostic factors in alveolar soft part sarcoma: a SEER analysis. J Surg Oncol. 2016;113:581–6.

    Google Scholar 

  87. Orbach D, Brennan B, Casanova M, et al. Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatr Blood Cancer. 2013;60:1826–32.

    Google Scholar 

  88. Viry F, Orbach D, Klijanienko J, Fréneaux P, Pierron G, Michon J, Neuenschwander S, Brisse HJ. Alveolar soft part sarcoma-radiologic patterns in children and adolescents. Pediatr Radiol. 2013;43:1174–81.

    Google Scholar 

  89. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dörken B. Chemotherapy in alveolar soft part sarcomas: what do we know? Eur J Cancer. 2003;39:1511–6.

    Google Scholar 

  90. Hilbert M, Mary P, Larroquet M, Serinet M-O, Helfre S, Brisse H, Coulomb A, Orbach D. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach? Pediatr Blood Cancer. 2012;58:475–6.

    Google Scholar 

  91. Souid A-K, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children’s Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010;55:1323–8.

    Google Scholar 

  92. Portera CA, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001;91:585–91.

    Google Scholar 

  93. Pink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35:249–52.

    Google Scholar 

  94. Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012;48:3036–44.

    Google Scholar 

  95. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682–90.

    Google Scholar 

  96. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15:1096–104.

    Google Scholar 

  97. Jagodzińska-Mucha P, Świtaj T, Kozak K, Koseła-Paterczyk H, Klimczak A, Ługowska I, Rogala P, Wągrodzki M, Falkowski S, Rutkowski P. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. Tumori. 2017;103:231–5.

    Google Scholar 

  98. Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122:1408–16.

    Google Scholar 

  99. Stacchiotti S, Mir O, Le Cesne A, et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist. 2017;23(1):62–70. https://doi.org/10.1634/theoncologist.2017-0161.

    Google Scholar 

  100. Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013;31:2296–302.

    Google Scholar 

  101. Judson I, Scurr M, Gardner K, Barquin E, Marotti M, Collins B, Young H, Jürgensmeier JM, Leahy M. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20:3603–12.

    Google Scholar 

  102. Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019;20(7):1023–34.

    Google Scholar 

  103. Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123:90–7.

    Google Scholar 

  104. Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105.

    Google Scholar 

  105. Mir O, Boudou-Rouquette P, Larousserie F, Blanchet B, Babinet A, Anract P, Goldwasser F. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. Anticancer Drugs. 2012;23:745–8.

    Google Scholar 

  106. Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, et al. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Ann Oncol. 2018;29(3):758–65.

    Google Scholar 

  107. O’Sullivan Coyne, et al. Phase II study of atezolizumab in patients with alveolar soft part sarcoma. Connective Tissue Oncology Society Annual Meeting. 2018.

    Google Scholar 

  108. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single arm, phase 2 trial. Lancet Oncol. 2019;20(6):837–48.

    Google Scholar 

  109. Sherman N, Vavilala M, Pollock R, Romsdahl M, Jaffe N. Radiation therapy for alveolar soft-part sarcoma. Med Pediatr Oncol. 1994;22:380–3.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France

    S. N. Dumont

  2. SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France

    D. Orbach

  3. Pathology Department, Armand Trousseau Pediatric Hospital, Paris, France

    A. Coulomb-L’herminé

  4. Pathology Department, Centre Oscar Lambret, Lille, France

    Y. M. Robin

Authors
  1. S. N. Dumont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Orbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Coulomb-L’herminé
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. M. Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. N. Dumont .

Editor information

Editors and Affiliations

  1. IUCT Oncopole, Institut Claudius Regaud, Toulouse, France

    Christine Chevreau

  2. Institut Bergonié, Bordeaux, France

    Antoine Italiano

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dumont, S.N., Orbach, D., Coulomb-L’herminé, A., Robin, Y.M. (2020). Alveolar Soft Part Sarcoma. In: Chevreau, C., Italiano, A. (eds) Rare Sarcomas. Springer, Cham. https://doi.org/10.1007/978-3-030-24697-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24697-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24696-9

  • Online ISBN: 978-3-030-24697-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation